Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sumatriptan succinate, quantity: 69.99 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; hypromellose; lactose monohydrate; titanium dioxide; triacetin; iron oxide red - sumatran tablets are indicated for the acute relief of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 600 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; hyprolose; lactose monohydrate; magnesium stearate; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - storcrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children. (see clinical trials; use in children)

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - naratriptan hydrochloride, quantity: 2.78 mg (equivalent: naratriptan, qty 2.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; lactose; titanium dioxide; hypromellose; indigo carmine; triacetin; iron oxide yellow - naramig tablets are indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; magnesium stearate; purified talc; povidone; titanium dioxide; maize starch; propylene glycol; hyprolose - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: glucose; propylene glycol; colloidal anhydrous silica; hyprolose; maize starch; povidone; hypromellose; magnesium stearate; titanium dioxide; purified talc - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

a. menarini singapore pte. ltd. - ergotamine tartrate; caffeine -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sumatriptan succinate, quantity: 139.98 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide - pharmacor sumatriptan is indicated for the acute relief of migraine attacks with or without aura.,there is no information available on the use of sumatriptan tablets in the treatment of basilar or hemiplegic migraine

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sumatriptan succinate, quantity: 69.99 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; titanium dioxide; triacetin; iron oxide red - pharmacor sumatriptan is indicated for the acute relief of migraine attacks with or without aura.,there is no information available on the use of sumatriptan tablets in the treatment of basilar or hemiplegic migraine